Overview

* Enovis ( ENOV ) Q2 net sales grow 7%, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats consensus, indicating strong operational performance

* Company reports Q2 net loss of $37 mln, reflecting profitability challenges

Outlook

* Enovis ( ENOV ) expects 2025 revenue between $2.245 bln and $2.275 bln

* Company forecasts 2025 adjusted EBITDA of $392-402 mln

* Enovis ( ENOV ) updates full-year adjusted EPS guidance to $3.05-$3.20

Result Drivers

* RECONSTRUCTIVE SALES - Reconstructive segment sales grew 11% year-over-year, driven by new product introductions

* STABLE MARKETS - Stable end markets contributed to overall sales growth of 7%

* NEW PRODUCTS - Encouraging momentum in new product introductions supported sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $564.54 $554.60

Sales mln mln (11

Analysts

)

Q2 Beat $0.79 $0.72

Adjusted (11

EPS Analysts

)

Q2 Gross 59.3%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Enovis Corp ( ENOV ) is $57.00, about 54.8% above its August 6 closing price of $25.76

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)